BiomX Inc. (NYSEMKT:PHGE - Get Free Report) traded down 2.3% on Tuesday . The stock traded as low as $0.93 and last traded at $0.94. 34,736 shares were traded during mid-day trading, a decline of 49% from the average session volume of 68,601 shares. The stock had previously closed at $0.96.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of BiomX in a report on Friday, August 16th.
View Our Latest Stock Report on PHGE
BiomX Trading Down 2.3 %
The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The business's 50-day moving average price is $1.11 and its two-hundred day moving average price is $2.48. The company has a market capitalization of $65.62 million, a price-to-earnings ratio of -1.54 and a beta of 1.29.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in BiomX stock. Ikarian Capital LLC bought a new position in shares of BiomX Inc. (NYSEMKT:PHGE - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,817,327 shares of the company's stock, valued at approximately $4,868,000. Ikarian Capital LLC owned about 19.59% of BiomX as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 40.57% of the company's stock.
About BiomX
(
Get Free Report)
BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BiomX, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BiomX wasn't on the list.
While BiomX currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
